肝脏类器官与代谢相关脂肪性肝病

摘要/Abstract

摘要： 全球代谢相关脂肪性肝病(MASLD/MASH)疾病负担愈来愈严重,对疾病潜在机制的理解不完全以及不同患者人群疾病病理生理学存在的显著差异,导致目前针对MASLD的治疗方法有限。3D类器官培养技术的进展,能够构建肝脏类器官模型,形成与人体肝脏生理病理环境更为相似的研究环境,进一步结合遗传学和基因组学,对深入探索人类代谢网络、研究MASLD发生机制,进而推进精准肝病学的发展具有重要意义。

关键词: 类器官, 肝脏类器官, 代谢相关脂肪性肝病, 功能基因组学

赵倩, 赵彩彦. 肝脏类器官与代谢相关脂肪性肝病[J]. 肝脏, 2024, 29(6): 628-630.

/ 推荐

参考文献

[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol,2019,70(1):151-171.
[2] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol,2023,79(6):1542-1556.
[3] Tacke F, Horn P, Wai-Sun Wong V, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol,2024.
[4] Osonoi S, Takebe T. Organoid-guided precision hepatology for metabolic liver disease[J]. J Hepatol,2024,80(5):805-821.
[5] Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration[J]. Nature,2013,494(7436):247-250.
[6] Huch M, Gehart H, van Boxtel R, et al. Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver[J]. Cell,2015,160(1-2):299-312.
[7] Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant[J]. Nature,2013,499(7459):481-484.
[8] Takebe T, Enomura M, Yoshizawa E, et al. Vascularized and Complex Organ Buds from Diverse Tissues via Mesenchymal Cell-Driven Condensation[J]. Cell Stem Cell, 2015,16(5):556-565.
[9] Ouchi R, Togo S, Kimura M, et al. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids[J]. Cell Metabolism,2019,30:374-384.e376.
[10] Hess A, Gentile SD, Ben Saad A, et al. Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease[J]. EMBO J,2023,42(24):e113898.
[11] Ramli MNB, Lim YS, Koe CT, et al. Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease[J]. Gastroenterology, 2020,159(4):1471-1486.e1412.
[12] Bauer S, Wennberg Huldt C, Kanebratt KP, et al. Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model[J]. Sci Rep,2017,7(1):14620.
[13] Tao T, Deng P, Wang Y, et al. Microengineered Multi-Organoid System from hiPSCs to Recapitulate Human Liver-Islet Axis in Normal and Type 2 Diabetes[J]. Adv Sci (Weinh),2022,9(5):e2103495.
[14] Wang Z, lv J, Zhang R, et al. Co-culture with fat cells induces cellular insulin resistance in primary hepatocytes[J]. Biochem Biophys Res Commun,2006,345(3):976-983.
[15] Zhou L, Sell H, Eckardt K, et al. Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes[J]. FEBS Lett,2007,581(22):4303-4308.
[16] Hendriks D, Brouwers JF, Hamer K, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis[J]. Nat Biotechnol, 2023,41(11):1567-1581.
[17] Tilson SG, Morell CM, Lenaerts AS, et al. Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells[J]. Hepatology,2021,74:2998-3017.
[18] Prill S, Caddeo A, Baselli G, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids[J]. Sci Rep,2019,9(1):11585.
[19] Kimura M, Azuma M, Zhang RR, et al. Digitalized Human Organoid for Wireless Phenotyping[J]. iScience,2018,4:294-301.
[20] Kimura M, Iguchi T, Iwasawa K, et al. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH[J]. Cell, 2022,185(22):4216-4232.e4216.